Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Perioperative Ivonescimab vs Pembrolizumab in Locally Advanced HNSCC
NCT06814067Phase 2Not yet recruiting
- Sponsor
- Fudan University
- Start
- Feb 2025
- Primary completion
- Feb 2029
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ivonescimab in head and neck squamous cell carcinoma (HNSCC), sponsored by Fudan University. Planned start Feb 2025; status: not yet recruiting.
02
Drugs
ivonescimab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT06814067.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06814067.